Abcam, ab274381, Anti-GLP-1R antibody [EPR23507-57] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal GLP-1R antibody. Carrier free. Suitable for IHC-P and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR23507-57,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab274381 is the carrier-free version of
ab254352
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GLP-1R also known as glucagon-like peptide-1 receptor plays an important role in glucose metabolism. This receptor is a member of the class B family of G protein-coupled receptors (GPCRs) and has a molecular mass of approximately 53 kDa. GLP-1R is expressed in pancreatic beta cells the central nervous system and other peripheral tissues. It binds to GLP-1 a peptide hormone initiating a cascade of intracellular signaling that is essential for its physiological functions.
Biological function summary
GLP-1R serves as an important player in the regulation of insulin secretion. It is not part of a complex but acts as a standalone receptor. When GLP-1 binds to GLP-1R it triggers the activation of adenylyl cyclase increasing cyclic AMP levels and facilitating insulin secretion. This process is glucose-dependent meaning that it enhances insulin release only when blood glucose levels are elevated therefore preventing hypoglycemia.
Pathways
GLP-1R is an integral component of the incretin signaling pathway and the insulin signaling pathway. Through these pathways it influences key metabolic processes. Incretin hormones like GLP-1 improve glucose-dependent insulin secretion involving proteins such as GLP-1R and other incretin-related receptors. Additionally GLP-1R interacts with insulin receptor pathways to modulate glucose uptake in tissues.
GLP-1R has significant implications in type 2 diabetes and obesity. Its role in enhancing insulin secretion makes it a target for therapeutic interventions using GLP-1 analogs like liraglutide. Liraglutide structure mimics natural GLP-1 effectively agonizing GLP-1R to achieve desired metabolic outcomes. Additionally liraglutide GLP-1 analog therapies show promise in obesity management by influencing appetite regulation through GLP-1R pathways in the central nervous system.